GENELUX CORPORATION Deferred Tax Liabilities, Gross
GENELUX CORPORATION (GNLX) had Deferred Tax Liabilities, Gross of $5.11 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-19
- 2025-12-31: Deferred Tax Liabilities, Gross $5.11M.
- 2024-12-31: Deferred Tax Liabilities, Gross $5.26M; Deferred Tax Liabilities, Gross as first filed $4.39M.
- 2023-12-31: Deferred Tax Liabilities, Gross $3.92M.
- 2022-12-31: Deferred Tax Liabilities, Gross $2.99M.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $5.11M 10-K · filed 2026-03-19 | |
| 2024-12-31 | $5.26M 10-K · filed 2026-03-19 | $4.39M 10-K · filed 2025-03-28 |
| 2023-12-31 | $3.92M 10-K · filed 2025-03-28 | |
| 2022-12-31 | $2.99M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |